Navigation Links
TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
Date:11/9/2009

Delft, the Netherlands, November 09, 2009 / b3c newswire /- Today, TNO, a Dutch contract research organization, and Seventh Wave, an American organization for contract research and consultancy, announce that the companies have signed a letter of intent with regard to TNOs dynamic in vitro gastrointestinal models TIM. The letter of intent proposes a collaboration in which Seventh Wave will obtain two TIM systems for commercialization in North America. The TIM systems will be used to determine the behavior of oral drug products and drug substances during passage through the gastrointestinal tract.

According to the terms stated in the letter of intent, TNO will supply its proprietary gastrointestinal models to Seventh Wave Laboratories, located in Chesterfield, Missouri. This central U.S. location, coupled with Seventh Waves customer responsiveness, will shorten study turnaround time for customers in North America. The TIM system has been validated for use in preclinical drug development. Both parties expect the TIM systems to be installed and ready for use by customers in the first quarter of 2010. In addition to the collaboration on the current models, the partners envisage joint projects to further validate the TIM system for new applications.

Niek Snoeij, CEO of TNO Quality of life, explains the benefits of the proposed collaboration as follows: The partnership with Seventh Wave allows us to capitalize on the strengths of the TIM system and offer extra capacity, flexibility, and faster turn-around times.

John Sagartz, President and CEO of Seventh Wave, adds: TIM compliments our current preclinical and clinical services. With the TIM system available on site, we have another valuable tool to solve our customers specific needs in formulation development and pharmacokinetics.

TNO gastroIntestinal Model (TIM)
By simulating accurately the human conditions in the gastrointestinal tract, the TIM system gives insight into the release, solubility, and availability for absorption of pharmaceuticals. This state-of-the-art, validated system has a much higher predictive value than regular dissolution tests. The computer-regulated model can simulate various physiologic states and helps scientists determine the bioaccessibility of active compounds and predict resultant blood concentration after single or repeated intake of various dosage forms.


TNO - http://www.tno.nl/pharma
TNO is an innovative, independent research organization. Through its expertise and the research it conducts, TNO contributes to the quality of work and life in the world. TNO supports and stimulates innovations in companies and organizations, thus improving the competitiveness of the economy. TNOs multidisciplinary approach and ability to apply research give it a unique position. More than 4300 professionals work at TNO.

Seventh Wave - www.7thwavelabs.com

Seventh Wave is a consulting and contract research organization providing integrated preclinical ADME/PK, pharmacology, toxicology, pathology, and clinical PK. With a continuous commitment to quality, Seventh Wave operates its consulting and laboratory services as an extension of its clients project teams in the design and timely execution of their preclinical development strategies.


Contact
(in US)
Albert Stevens
Tel: +31 6 15631194

(in Europe)
Heather Wagner
Tel: +31 306944615

Info-pharma@tno.nl
www.tno.nl/pharma


'/>"/>
b3c newswire

Related biology news :

1. AACR to host Seventh Annual International Conference on Frontiers in Cancer Prevention Research
2. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
3. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
4. FEBS Letters Structured Digital Abstracts experiment
5. BIO-key(R) Issues Open Letter to Shareholders
6. Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company
7. Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company
8. Selected personal letters of Max Perutz are released in new book
9. NEWSLETTER: Antibody Fragment Production Breakthrough with 2nd Generation EBA
10. Taser Notices Intent to Serve Subpoena for Information on Old NIJ Tests in Taser v. Stinger
11. Wii bit of fun at Rice University has serious intent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology: